Gri Bio Etf Profile
| GRI Etf | USD 3.26 0.06 1.81% |
PerformanceWeakest
| Odds Of DistressLow
|
GRI Bio is trading at 3.26 as of the 31st of January 2026. This is a 1.81% down since the beginning of the trading day. The etf's open price was 3.32. GRI Bio has less than a 10 % chance of experiencing some financial distress in the next two years of operation, but has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 2nd of November 2025 and ending today, the 31st of January 2026. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 10th of February 2021 | Category Healthcare | Classification Health Care |
The investment seeks investment results that correspond generally to the performance, before the funds fees and expenses, of an index called the Cohen Steers Global Realty Majors Index. Cohen Steers is traded on Archipelago Exchange in USA. The company has 536.3 K outstanding shares of which 700.75 K shares are currently shorted by investors with about 0.15 days to cover. More on GRI Bio
Moving against GRI Etf
GRI Etf Highlights
| President Director | Marc Hertz |
| Old Name | Gino Rossi S.A. |
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) |
| Average Analyst Recommendation Analysts covering GRI Bio report their recommendations after researching GRI Bio's financial statements, talking to executives and customers, or listening in on GRI Bio's conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering GRI Bio. The GRI consensus assessment is calculated by taking the average forecast from all of the analysts covering GRI Bio. | |
| Total Current Liabilities | 1.64 Million |
| Total Stockholder Equity | 4.03 Million |
| Currency Code | USD |
| Fiscal Year End | December |
| Stock Based Compensation | 148,000 |
| Property Plant And Equipment Net | 124,000 |
| Begin Period Cash Flow | 1.81 Million |
| Net Debt | (4.91 Million) |
| Accounts Payable | 897,000 |
| Cash | 5.03 Million |
| Other Operating Expenses | 8.23 Million |
| Non Current Assets Total | 124,000 |
| Cash And Short Term Investments | 5.03 Million |
| 50 Day M A | 22.9004 |
| Code | GRI |
| Common Stock Shares Outstanding | 6,546 |
GRI Bio [GRI] is traded in USA and was established 2008-05-07. GRI Bio is listed under Biotechnology category by Fama And French industry classification. The fund is classified under Health Care category within Biotechnology family. GRI Bio currently have 5.74 M in assets under management (AUM). , while the total return for the last 3 years was 8.99%.
GRI Bio has about 183.82 M in cash with (8.61 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.3.
Check GRI Bio Probability Of Bankruptcy
GRI Bio Risk Profiles
The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in GRI Bio. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures.
| Mean Deviation | 7.57 | |||
| Standard Deviation | 11.25 | |||
| Variance | 126.51 | |||
| Risk Adjusted Performance | (0.21) |
GRI Bio Technical Analysis
Transformation |
The output start index for this execution was zero with a total number of output elements of sixty-one. GRI Bio Inverse Tangent Over Price Movement function is an inverse trigonometric method to describe GRI Bio price patterns.
GRI Bio Against Markets
GRI Etf Analysis Notes
The fund retains 99.63% of assets under management (AUM) in equities. GRI Bio last dividend was 0.511 per share. The investment seeks investment results that correspond generally to the performance, before the funds fees and expenses, of an index called the Cohen Steers Global Realty Majors Index. Cohen Steers is traded on Archipelago Exchange in USA. To learn more about GRI Bio call the company at 619 400 1170 or check out https://www.gribio.com.GRI Bio Investment Alerts
| GRI Bio generated a negative expected return over the last 90 days | |
| GRI Bio has high historical volatility and very poor performance | |
| GRI Biohas 700,747 shares shorted by GRI Bio investors is about 100% of outstending shares | |
| The company reported the last year's revenue of 22.54 M. Reported Net Loss for the year was (8.21 M) with profit before taxes, overhead, and interest of 0. | |
| GRI Bio has about 183.82 M in cash with (8.61 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.3. | |
| Latest headline from finance.yahoo.com: GRI Bio Delivers Compelling New Phase 2a Gene Expression Data Demonstrating Improvements in Key Drivers of Fibrosis and Lung Repair in IPF | |
| The fund retains 99.63% of its assets under management (AUM) in equities |
GRI Market Capitalization
The company currently falls under 'Nano-Cap' category with a total capitalization of 1.75 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate GRI Bio's market, we take the total number of its shares issued and multiply it by GRI Bio's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.Management Efficiency
GRI Bio has Return on Asset of (1.3752) % which means that on every $100 spent on assets, it lost $1.3752. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (3.9784) %, meaning that it generated no profit with money invested by stockholders. GRI Bio's management efficiency ratios could be used to measure how well GRI Bio manages its routine affairs as well as how well it operates its assets and liabilities.The strategic initiatives led by GRI Bio's management are central to its market success. By analyzing these initiatives, we provide a clear picture of the stock's growth prospects.
Top GRI Bio Etf Constituents
| PLD | Prologis | Stock | |
| EQIX | Equinix | Stock | |
| SBAC | SBA Communications Corp | Stock | |
| AMT | American Tower Corp | Stock | |
| SPG | Simon Property Group | Stock | |
| MITEF | Mitsubishi Estate Co | Pink Sheet | |
| VTR | Ventas Inc | Stock | |
| AVB | AvalonBay Communities | Stock | |
| EQR | Equity Residential | Stock | |
| WELL | Welltower | Stock | |
| PSA | Public Storage | Stock | |
| DLR | Digital Realty Trust | Stock |
Institutional Etf Holders for GRI Bio
Have you ever been surprised when a price of an equity instrument such as GRI Bio is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading GRI Bio backward and forwards among themselves. GRI Bio's institutional investor refers to the entity that pools money to purchase GRI Bio's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Note, although GRI Bio's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses. GRI Bio Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific GRI Bio insiders, such as employees or executives, is commonly permitted as long as it does not rely on GRI Bio's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases GRI Bio insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Hertz Walter Marc over three weeks ago Acquisition by Hertz Walter Marc of 129730 shares of GRI Bio at 0.6857 subject to Rule 16b-3 | ||
Hertz Walter Marc over three months ago Acquisition by Hertz Walter Marc of 103067 shares of GRI Bio at 1.93 subject to Rule 16b-3 | ||
Szekeres David Leslie over three months ago Acquisition by Szekeres David Leslie of 10276 shares of GRI Bio at 1.41 subject to Rule 16b-3 | ||
Leanne Kelly over three months ago Acquisition by Leanne Kelly of 11854 shares of GRI Bio at 1.41 subject to Rule 16b-3 | ||
Szekeres David Leslie over three months ago Acquisition by Szekeres David Leslie of 7545 shares of GRI Bio at 1.3 subject to Rule 16b-3 | ||
Rongen Roelof over a year ago Acquisition by Rongen Roelof of 30297 shares of GRI Bio at 0.6857 subject to Rule 16b-3 | ||
Kelly Leanne over a year ago Acquisition by Kelly Leanne of 83333 shares of GRI Bio subject to Rule 16b-3 | ||
Agro Albert over a year ago Acquisition by Agro Albert of 172189 shares of GRI BIO subject to Rule 16b-3 |
GRI Bio Outstanding Bonds
GRI Bio issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. GRI Bio uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most GRI bonds can be classified according to their maturity, which is the date when GRI Bio has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View |
GRI Bio Predictive Daily Indicators
GRI Bio intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of GRI Bio etf daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
GRI Bio Forecast Models
GRI Bio's time-series forecasting models are one of many GRI Bio's etf analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary GRI Bio's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.Other Information on Investing in GRI Etf
GRI Bio financial ratios help investors to determine whether GRI Etf is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in GRI with respect to the benefits of owning GRI Bio security.